The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Operations of Line II was stopped due to a fire incident earlier
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
The pilot plant is focused on scaling up beverage production and will support applications
Lonza plans to invest approximately CHF 500 million to upgrade the facility
A five-day inspection was concluded successfully with no critical and no major observations raised
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Subscribe To Our Newsletter & Stay Updated